Holen Sie sich die Stockscreener-App
3.08
0.65%
-0.02
Handel nachbörslich:
3.16
0.08
+2.60%
Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten
Piper starts Aquestive at overweight, cites allergy reaction treatment - MSN
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates - MSN
Institutional investors own a significant stake of 49% in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Yahoo Finance
Cantor Fitzgerald Weighs in on AQST FY2025 Earnings - MarketBeat
Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in December - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Anaphylaxis Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics - Barchart
Neuromuscular Disease Therapeutics Market to grow by USD 13.7 Billion from 2025-2029, driven by novel approvals, with AI impacting market trendsTechnavio - The Malaysian Reserve
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress - TipRanks
Aquestive Therapeutics Provides Business Update - citybiz
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives - The Manila Times
Aquestive Therapeutics Targets 2026 Launch for Anaphylm as FDA Approves Pediatric Seizure Drug - StockTitan
Aquestive Therapeutics: Five Foci For 2025 (NASDAQ:AQST) - Seeking Alpha
Geode Capital Management LLC Has $8.31 Million Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Barclays PLC Buys 73,542 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
What Analysts Were Expecting After Aquestive Therapeutics Inc (NASDAQ: AQST) rose 4.21% - Stocks Register
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial Corp - Defense World
State Street Corp Has $7.45 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
State Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Stifel Financial Corp Sells 301,538 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics’ (AQST) “Buy” Rating Reiterated at HC Wainwright - Defense World
Aquestive receives FDA Orphan Drug Exclusivity for Libervant - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Aquestive shares reiterated at Buy by analyst as FDA grants ODE to Libervant - Investing.com Canada
Aquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC Wainwright - MarketBeat
Analysts Set Expectations for AQST FY2024 Earnings - Defense World
Wellington Management Group LLP Invests $922,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment - Yahoo Finance
Aquestive Therapeutics Receives U.S. FDA Orphan Drug - GlobeNewswire
Cantor Fitzgerald Forecasts AQST FY2024 Earnings - MarketBeat
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25% - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by BNP Paribas Financial Markets - Defense World
Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Charles Schwab Investment Management Inc. Purchases 9,268 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics' SWOT analysis: stock poised for growth with innovative epinephrine delivery - Investing.com Australia
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside - Yahoo Finance UK
Aquestive Therapeutics (NASDAQ:AQST) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Aquestive Therapeutics stock initiated at Overweight by Fitzgerald, eyes strong 2025 catalysts - Investing.com UK
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year - Yahoo Finance
Aquestive Therapeutics (NASDAQ:AQST) shareholders have earned a 88% return over the last year - Simply Wall St
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth - Investing.com Nigeria
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth By Investing.com - Investing.com South Africa
1.11%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):